A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
Genentech, Inc.
Study ID
NCT01075464
Phase
PHASE1
Status
Completed

Conditions

  • Solid Cancers

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • MEGF0444A — DRUG
    Intravenous escalating dose
  • bevacizumab — DRUG
    Intravenous repeating dose
  • paclitaxel — DRUG
    Intravenous repeating dose

Study Details

This is a Phase Ib, open-label, dose-escalation study of MEGF0444A in combination with bevacizumab, and in combination with bevacizumab and paclitaxel as therapy for locally advanced or metastatic solid tumors.

Key Dates

First listed
Feb 25, 2010
Start date
Feb 28, 2010
Status verified
Nov 2016
Primary completion
Apr 30, 2013
Completion
Apr 30, 2013

Study Design

Enrollment
64 participants (actual)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: A
  • Experimental: B

Primary Outcome Measure

Incidence and nature of dose-limiting toxicities (DLTs) [ Time Frame: Days 1 to 28 of Cycle 1 ]

Locations (5)

FacilityCityStateZIPSite coordinators
-ScottsdaleArizona85258-
-San FranciscoCalifornia94115-
-Santa MonicaCalifornia90404-
-TampaFlorida33612-
-NashvilleTennessee37203-

Related Studies